- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00894660
A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects
April 20, 2010 updated by: Pfizer
The study will determine if amodiaquine tablet (Pfizer), an antimalaria agent, is pharmaceutically equivalent to a comparator product (Arsuamoon-Guilin China).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Singapore, Singapore, 188770
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive.
- BMI of 18 to 30 kg/m2; and a total body weight >45 kg (99 lbs).
- An informed consent document signed and dated by the subject or a legally acceptable representative.
Exclusion Criteria:
- Evidence or history of clinically significant abnormalities.
- A positive urine drug screen, history of regular alcohol consumption.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Amodiaquine (Pfizer)
|
Oral tablet, single dose, 1 X 300 MG
Other Names:
|
Active Comparator: Amodiaquine tablets (Arsuamoon-Guilin China)
|
Oral tablet, single dose, 2 X 150 MG
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC and Cmax of amodiaquine
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tolerability
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (Actual)
July 1, 2009
Study Completion (Actual)
July 1, 2009
Study Registration Dates
First Submitted
May 4, 2009
First Submitted That Met QC Criteria
May 5, 2009
First Posted (Estimate)
May 7, 2009
Study Record Updates
Last Update Posted (Estimate)
April 21, 2010
Last Update Submitted That Met QC Criteria
April 20, 2010
Last Verified
April 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B0731004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Falciparum Malaria
-
University of OxfordTerminatedP. Falciparum MalariaThailand
-
National Institute of Allergy and Infectious Diseases...CompletedAccute Falciparum MalariaMali
-
Medical University of ViennaInternational Centre for Diarrhoeal Disease Research, Bangladesh; Armed Forces...CompletedAzithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in BangladeshUncomplicated Falciparum MalariaBangladesh
-
Medecins Sans Frontieres, NetherlandsUniversity of Oxford; Mahidol University; Disease Control, Department of Health...UnknownUncomplicated Falciparum MalariaMyanmar
-
University of OxfordNanyang Technological University; Texas Biomedical Research InstituteCompletedP. Falciparum Malaria | P. Falciparum Malaria Mixed InfectionThailand
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Universidad Nacional de ColombiaSanofi Pasteur, a Sanofi CompanyCompleted
-
National Institute for Medical Research, TanzaniaWorld Health Organization; Muhimbili University of Health and Allied SciencesCompletedUncomplicated Falciparum MalariaTanzania
-
University of OxfordCompletedSevere Falciparum MalariaBangladesh
-
Heidelberg UniversityCompletedUncomplicated Falciparum MalariaBurkina Faso
Clinical Trials on Amodiaquine (Test)
-
University of Yaounde 1Malaria Research Capacity Development in West and Central Africa Consortium; Developing Excellence in Leadership, Training and Science Africa Initiative and other collaboratorsCompleted
-
London School of Hygiene and Tropical MedicineCompleted
-
Charite University, Berlin, GermanyKintampo Health Research Centre, Ghana; University for Development Studies,...Unknown
-
Swiss Federal Institute of TechnologySwiss National Science Foundation; Swiss Tropical & Public Health InstituteCompleted
-
London School of Hygiene and Tropical MedicineUniversity of NairobiCompletedMalaria, FalciparumKenya
-
PfizerCompleted
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitTerminatedHealthy | Pharmacokinetic | Drug CombinationThailand
-
Heidelberg UniversityCompleted
-
Bandim Health ProjectCompleted
-
SanofiMedicines for Malaria VentureCompleted